ValuEngine lowered shares of Sophiris Bio (NASDAQ:SPHS) from a hold rating to a sell rating in a report published on Tuesday, ValuEngine reports.

Several other equities analysts have also recently commented on the stock. Maxim Group reissued a hold rating on shares of Castle Brands in a research report on Wednesday, June 19th. HC Wainwright dropped their target price on shares of Sophiris Bio from $10.00 to $3.50 and set a buy rating on the stock in a research report on Thursday, March 14th. Finally, Piper Jaffray Companies dropped their target price on shares of Sophiris Bio to $5.00 and set an overweight rating on the stock in a research report on Wednesday, March 13th.

Shares of NASDAQ SPHS opened at $1.05 on Tuesday. Sophiris Bio has a fifty-two week low of $0.71 and a fifty-two week high of $3.49. The company has a market cap of $30.22 million, a PE ratio of -2.02 and a beta of 2.80. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.00 and a current ratio of 2.00. The company has a 50-day simple moving average of $0.83.

Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. As a group, equities analysts predict that Sophiris Bio will post -0.36 EPS for the current fiscal year.

An institutional investor recently raised its position in Sophiris Bio stock. Geode Capital Management LLC grew its position in shares of Sophiris Bio Inc (NASDAQ:SPHS) by 14.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 243,523 shares of the biopharmaceutical company’s stock after buying an additional 31,579 shares during the quarter. Geode Capital Management LLC owned 0.81% of Sophiris Bio worth $202,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 8.27% of the company’s stock.

Sophiris Bio Company Profile

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Featured Article: Holder of Record

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.